Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Ionis Pharmaceuticals Inc’s stock clocked out at $41.82, down -2.04% from its previous closing price of $42.69. In other words, the price has decreased by -$2.04 from its previous closing price. On the day, 1.57 million shares were traded. IONS stock price reached its highest trading level at $43.0619 during the session, while it also had its lowest trading level at $41.8.
Ratios:
To gain a deeper understanding of IONS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On July 01, 2025, Barclays Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $57. On April 07, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $45.H.C. Wainwright initiated its Buy rating on April 07, 2025, with a $45 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when BENNETT C FRANK sold 10,000 shares for $43.98 per share. The transaction valued at 439,776 led to the insider holds 93,466 shares of the business.
BENNETT C FRANK bought 16,000 shares of IONS for $703,642 on Aug 18 ’25. On Aug 06 ’25, another insider, PARSHALL B LYNNE, who serves as the Director of the company, sold 5,000 shares for $41.93 each. As a result, the insider received 209,646 and left with 86,344 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6665732096 and an Enterprise Value of 6495444480. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.06 while its Price-to-Book (P/B) ratio in mrq is 10.54. Its current Enterprise Value per Revenue stands at 6.88 whereas that against EBITDA is -25.455.
Stock Price History:
The Beta on a monthly basis for IONS is 0.28, which has changed by -0.13505685 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $50.43, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 1.20%, while the 200-Day Moving Average is calculated to be 18.34%.
Shares Statistics:
It appears that IONS traded 1.92M shares on average per day over the past three months and 1879350 shares per day over the past ten days. A total of 159.20M shares are outstanding, with a floating share count of 158.08M. Insiders hold about 0.82% of the company’s shares, while institutions hold 106.44% stake in the company. Shares short for IONS as of 1753920000 were 11580340 with a Short Ratio of 6.03, compared to 1751241600 on 14139627. Therefore, it implies a Short% of Shares Outstanding of 11580340 and a Short% of Float of 9.64.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Ionis Pharmaceuticals Inc (IONS) in the stock market.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.67 and low estimates of -$1.37.
Analysts are recommending an EPS of between -$1.6 and -$2.49 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.63, with 12.0 analysts recommending between $0.25 and -$2.98.
Revenue Estimates
In the current quarter, 19 analysts expect revenue to total $131.5M. It ranges from a high estimate of $172.61M to a low estimate of $111.1M. As of the current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 19 analysts are estimating revenue of $145.55M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $120.54M.
A total of 26 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $836M, resulting in an average revenue estimate of $866.83M. In the same quarter a year ago, actual revenue was $705MBased on 25 analysts’ estimates, the company’s revenue will be $926.78M in the next fiscal year. The high estimate is $1.35B and the low estimate is $687.38M.